Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H23FN4OS.2ClH |
| Molecular Weight | 459.408 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.CC1=C(NC(=O)[C@@H](N)CCCCN)C=CC(=C1)C2=NC3=C(S2)C=CC(F)=C3
InChI
InChIKey=QZSMNTOCJVVFEU-CKUXDGONSA-N
InChI=1S/C20H23FN4OS.2ClH/c1-12-10-13(20-25-17-11-14(21)6-8-18(17)27-20)5-7-16(12)24-19(26)15(23)4-2-3-9-22;;/h5-8,10-11,15H,2-4,9,22-23H2,1H3,(H,24,26);2*1H/t15-;;/m0../s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/15377855 | https://www.ncbi.nlm.nih.gov/pubmed/15634650Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800021353
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15377855 | https://www.ncbi.nlm.nih.gov/pubmed/15634650
Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800021353
5F-DF-203-L-LYSINAMIDE (Phortress) is an experimental antitumor agent with potent and selective activity against
human-derived carcinomas of breast, ovarian and renal origin. The mechanism of action of Phortress is distinct from all classes of chemotherapeutic
agents currently in the clinic, and involves metabolic activation by cytochrome P450 (CYP) 1A1 to electrophilic
species, which generate DNA adducts in sensitive tumors only. Phortress is in phase I clinical trials for the treatment of solid tumours. The compound was co-developed by Pharminox, University of Nottingham and Cancer Research UK.
Originator
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.31 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19088497 |
10 mg/kg single, intravenous dose: 10 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
PHORTRESS plasma | Mus musculus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.27 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19088497 |
10 mg/kg 1 times / week multiple, intravenous dose: 10 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
PHORTRESS plasma | Mus musculus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3.239 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19088497 |
10 mg/kg single, intravenous dose: 10 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
PHORTRESS plasma | Mus musculus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
5.415 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19088497 |
10 mg/kg 1 times / week multiple, intravenous dose: 10 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
PHORTRESS plasma | Mus musculus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Sample Use Guides
50 patients were treated with 145 cycles of 5F-DF-203-L-LYSINAMIDE (Phortress) over a dose range of 3-50mg/m2. The first 6 patients were treated on d1,8 Q4weeks, 2 patients having DLTs. The protocol was amended to d1 q3weekly dosing, and escalated from 3 to 50 mg/m2 over 10 cohorts.
Route of Administration:
Intravenous
5F-DF-203-L-LYSINAMIDE caused a concentration-dependent cytokine response in precision-cut lung slice (PCLS) model. Exposure to 25uM 5F-DF-203-L-LYSINAMIDE modestly elevated TNF-α within 24h, with average levels of TNF-α in PCLS
reaching 25 pg/mg, just above assay LLOD. Exposure to 25uM 5F-DF-203-L-LYSINAMIDE for 72h increased tissue levels of IL-β, IL-5, and CINC. Exposure
to 50 and 100uM caused significant increases in PCLS content for all six cytokines analyzed.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
328087-38-3
Created by
admin on Sat Dec 16 11:18:26 GMT 2023 , Edited by admin on Sat Dec 16 11:18:26 GMT 2023
|
PRIMARY | |||
|
5F-DF-203-L-LYSINAMIDE
Created by
admin on Sat Dec 16 11:18:26 GMT 2023 , Edited by admin on Sat Dec 16 11:18:26 GMT 2023
|
PRIMARY | Substd. 2-arylbenzazole cpds. and their use as antitumour agents. | ||
|
SUB194064
Created by
admin on Sat Dec 16 11:18:26 GMT 2023 , Edited by admin on Sat Dec 16 11:18:26 GMT 2023
|
PRIMARY | |||
|
9804228
Created by
admin on Sat Dec 16 11:18:26 GMT 2023 , Edited by admin on Sat Dec 16 11:18:26 GMT 2023
|
PRIMARY | |||
|
PHORTRESS
Created by
admin on Sat Dec 16 11:18:26 GMT 2023 , Edited by admin on Sat Dec 16 11:18:26 GMT 2023
|
PRIMARY | Phortress rapidly reverts to 5-fluoro 203 in carcinoma cell lines, resulting in significant growth inhibition at nanomolar concentrations.2 At 20 mg/kg, phortress can suppress the growth of breast and ovarian xenografts in vivo. | ||
|
710305
Created by
admin on Sat Dec 16 11:18:26 GMT 2023 , Edited by admin on Sat Dec 16 11:18:26 GMT 2023
|
PRIMARY | |||
|
100000178336
Created by
admin on Sat Dec 16 11:18:26 GMT 2023 , Edited by admin on Sat Dec 16 11:18:26 GMT 2023
|
PRIMARY | |||
|
AXR52N9SMF
Created by
admin on Sat Dec 16 11:18:26 GMT 2023 , Edited by admin on Sat Dec 16 11:18:26 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
